Nutranext

Based on cost efficient operations, strong market share and revenue boosting efforts, one analyst upgraded Clorox Co. (NYSE: CLX). The Analyst Argus analyst John Staszak upgraded Clorox from Hold to Buy and set a price target of $175. The Thesis Clorox has produced positive earnings per...